Metsera Inc., a clinical-stage biopharmaceutical company, has announced it will present new research at the 85th Scientific Sessions of the American Diabetes Association. The company will showcase its next-generation obesity portfolio, including clinical and preclinical findings from its lead program, MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist. The presentations will include clinical data from MET-097i's completed Phase 1/2 trial, alongside preclinical data on MET-233i, a monthly, ultra-long acting amylin analog. These presentations aim to highlight Metsera's scalable and differentiated approaches to treating overweight and obesity. Further details about the company's presence at the ADA meeting can be found on their website.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。